SCHEMBL16570355

SCHEMBL16570355

CS(=O)(=O)c1cccc(Cn2ccc3cnc(Nc4ccc5c(c4)CC(=O)N5)nc32)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2B Q14289 9/20 0.61
▸ PTK2 Q05397 9/20 0.61
▸ ULK1 O75385 2/20 0.61
▸ AURKA O14965 3/20 0.54
▸ CDK1 P06493 2/20 0.54
▸ JAK3 P52333 2/20 0.54
▸ DCLK1 O15075 1/20 0.54
▸ PDPK1 O15530 1/20 0.54
▸ JAK2 O60674 1/20 0.54
▸ ROCK2 O75116 1/20 0.54
▸ PRKD3 O94806 1/20 0.54
▸ MAP4K4 O95819 1/20 0.54
▸ EGFR P00533 1/20 0.54
▸ NTRK1 P04629 1/20 0.54
▸ PRKCG P05129 1/20 0.54
▸ LCK P06239 1/20 0.54
▸ FYN P06241 1/20 0.54
▸ LYN P07948 1/20 0.54
▸ RET P07949 1/20 0.54
▸ IGF1R P08069 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16571393 0.93 ULK1 (0.62) PTK2BPTK2ULK1AURKACDK1
SCHEMBL16570837 0.85 ULK1 (0.53) PTK2BPTK2ULK1AURKACDK1
SCHEMBL16570474 0.85 BCL6 (0.59) PTK2BPTK2ULK1AURKACDK1
SCHEMBL16571235 0.82 PTK2 (0.51) PTK2BPTK2ULK1AURKACDK1
SCHEMBL16570363 0.81 PTK2 (0.51) PTK2BPTK2ULK1AURKACDK1
SCHEMBL16570609 0.81 PTK2B (0.55) PTK2BPTK2ULK1AURKACDK1
SCHEMBL16571003 0.80 PTK2 (0.65) PTK2BPTK2AURKACDK1JAK3
SCHEMBL16571083 0.79 PTK2 (0.54) PTK2BPTK2ULK1AURKACDK1
SCHEMBL16570923 0.79 PTK2 (0.68) PTK2BPTK2AURKACDK1JAK3
SCHEMBL6209873 0.78 PTK2 (0.79) PTK2BPTK2ULK1AURKACDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN PTK2B 13/4885PTK2 2/4885ULK1 769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback